Global Blood Therapeutics, Inc. (GBT): Price and Financial Metrics

Global Blood Therapeutics, Inc. (GBT): $68.49

0.01 (+0.01%)

POWR Rating

Component Grades








Add GBT to Watchlist
Sign Up

Industry: Biotech




#111 of 385

in industry

GBT Price/Volume Stats

Current price $68.49 52-week high $73.02
Prev. close $68.48 52-week low $21.65
Day low $68.47 Volume 3,279,900
Day high $68.49 Avg. volume 2,065,836
50-day MA $62.32 Dividend yield N/A
200-day MA $38.21 Market Cap 4.62B

GBT Stock Price Chart Interactive Chart >

Global Blood Therapeutics, Inc. (GBT) Company Bio

Global Blood Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. The company was founded in 2012 and is based in San Francisco, California.

GBT Latest News Stream

Event/Time News Detail
Loading, please wait...

GBT Latest Social Stream

Loading social stream, please wait...

View Full GBT Social Stream

Latest GBT News From Around the Web

Below are the latest news stories about GLOBAL BLOOD THERAPEUTICS INC that investors may wish to consider to help them evaluate GBT as an investment opportunity.

GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022

Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease PatientsSOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022, which was introduced today and, if passed in its current form, would authorize for appropriations of $535 million in annual funding to support sickle cell d

Yahoo | September 15, 2022

GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference

Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human ServicesSOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 11th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 14th. The virtual conference, which takes place during National Sickle Cell Awareness Mon

Yahoo | September 8, 2022

Global Blood (GBT) Up 1.9% Since Last Earnings Report: Can It Continue?

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 7, 2022

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Yahoo | August 29, 2022

Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023

Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.

Yahoo | August 12, 2022

Read More 'GBT' Stories Here

GBT Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 65.96%
5-year 24.87%
2023 N/A
2022 0.00%
2021 -32.42%
2020 -45.52%
2019 93.64%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!